IO Biotech Announces Acceptance of Abstract to be Presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting

• New nonclinical data strengthen evidence of individual contribution of IO102 and IO103 in controlling tumor growth
  

NEW YORK, March 06, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win platform, today announced that an abstract has been accepted for presentation at the American Association for Cancer Research Annual Meeting 2024 (AACR 2024), taking place April 5-10, 2024 in San Diego, CA. The poster will include nonclinical data related to IO Biotech’s lead therapeutic cancer vaccine candidate, IO102-IO103, currently being evaluated in a pivotal Phase 3 study.

“We are excited with our new nonclinical data clearly demonstrating how the dual antigen vaccine IO102-IO103 differentially contribute to the anti-tumor effect: while IO102 treatment results in the reduction of the immune suppression in the TME, IO103 appears to impact by enhancement of T effector function,” said Mai-Britt Zocca, Ph.D., President and CEO of IO Biotech. “These findings further support the potential that co-administration of the dual antigen vaccine IO102-IO103 can benefit patients due to its impact on two separate immune resistance pathways, IDO1 and PD-L1, respectively.”

Presentation Details

Poster Title: Immune modulatory cancer vaccines against IDO1 and PD-L1 trigger distinct pathways and cooperatively reduce tumor growth in preclinical models
Session Title: Vaccines, Antigens, and Antigen Presentation 1
Session Date and Time: Tuesday Apr 9, 2024 9:00 AM - 12:30 PM
Location: Poster Section 5
Poster Board Number: 5
Poster Abstract Number: 4094

About IO102-IO103

IO102-IO103 is an investigational off-the-shelf therapeutic cancer vaccine designed to kill both tumor cells and immune-suppressive cells in the tumor microenvironment (TME) by stimulating activation and expansion of T cells against indoleamine 2,3-dioxygenase (IDO) and/or programmed death-ligand 1 (PD-L1) cells. The company is currently conducting a pivotal Phase 3 trial (IOB-013/KN-D18; NCT05155254) investigating IO102-IO103 in combination with pembrolizumab versus pembrolizumab alone in patients with advanced melanoma, a Phase 2 basket trial (IOB-022/KN-D38; NCT05077709) investigating IO102-IO103 in combination with pembrolizumab as first line treatment in patients with solid tumors, and a Phase 2 basket trial (IOB-032/PN-E40; NCT05280314) investigating IO102-IO103 in combination with pembrolizumab as neo-adjuvant/adjuvant treatment of patients with solid tumors.